Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Autor:	Noam Benyamini, Miri Zektser, Odit Gutwein, Nadav Sarid, Gilad Itchaki, Anatoly Nemets, Uri Abadi, Nagib Dally, Shimrit Harlev, Kalman Filanovsky, Elena Ribakovsky, Merav Leiba, Netanel A Horwitz, Ron Ram, Chava Perry, Ronit Gurion, Abraham Avigdor, Orit Sofer, Irit Avivi, Yafit Segman, Neta Goldschmidt, Tamar Tadmor, Yair Herishanu, Vladimir Vainstein, Yair Goldhecht
Rok vydání:	2020
Předmět:	Oncology Cancer Research medicine.medical_specialty Immunoconjugates Clinical study 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Retrospective Studies business.industry Antibodies Monoclonal Retrospective cohort study Hematology medicine.disease humanities Lymphoma Polatuzumab vedotin Regimen Treatment Outcome 030220 oncology & carcinogenesis Relapsed refractory Lymphoma Large B-Cell Diffuse Neoplasm Recurrence Local business Diffuse large B-cell lymphoma 030215 immunology
Zdroj:	Leukemialymphoma. 62(1)
ISSN:	1029-2403
Popis:	The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed7fd719426bd3d6751ddebcaf37b3a https://pubmed.ncbi.nlm.nih.gov/32981410 Zobrazit plný text záznamu